Vis børsmeldingen
business and corporate development activities and be a key contributor to the
strategic decision making for the existing pipeline and to capture new
opportunities.
Over the last twenty-five years, Ludovic has held numerous international
managerial positions providing leadership in the pharmaceutical industry in the
areas of international research and development, business development, as well
as marketing and sales. In particular, he has participated in the launch of more
than fifteen original orphan drugs or specialty pharmaceuticals.
Mr Robin began his career as a scientist developing new cosmetic and
dermatological formulations. Subsequently he held various managerial and
leadership roles in sales, marketing and business development at L’Ore?al,
Servier and Laboratoires Expanscience. During this period, he originated, signed
and executed thirteen commercial partnerships in more than twenty countries. In
2004, Ludovic joined Shire for the launch of their dermatology and nephrology
franchises. During his twelve years with the company, he went on to serve as
Marketing Manager, Business Unit Director, Marketing Director and Commercial
Operations Head of France/Benelux. While at Shire he was a member of the French
Executive Board from 2008 to 2016. In 2016 he joined Advicenne, a French biotech
listed on Euronext (Paris-Brussels) as CBO, deputy CEO, responsible for
commercial strategy of the drug candidates under development/registration in EU
and US.
Mr Robin holds a Doctor of Pharmacy (PharmD) from Lyon I University, a Master’s
in Industrial Pharmacy from Lyon Institute of Industrial Pharmacy, and an MBA
from HEC Paris.
Per Walday, CEO, comments: “We are delighted to welcome Ludovic to PCI Biotech.
With his broad commercial insight and experience from both biotech and larger
organisations, he will bring key value onboard in an exciting phase of PCI
Biotech’s development towards potential commercialisation.”
Ludovic Robin added: “I am excited to be joining PCI Biotech and I am impressed
by the company’s progress this far. My focus will of course be on the strategic
decision making and execution of the commercialisation strategy for fimaChem,
but I am also enthused by the opportunity space for both the fimaVacc and
fimaNAc assets.”
Mr Ludovic Robin will commence as CBO in May.
For further information, please contact:
Per Walday, CEO
Email: pw@pcibiotech.no
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Kilde
